Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Fig. 1

Kaplan-Meier curve of overall survival (a, c, e), progression-free survival (b, d, f). a The median survival time was 12.9 months. b The median progression-free survival was 9.9 months. c The median survival times were 17.4 months in patients with MGMT promoter hypermethylation (N = 11), and 11.8 months in those with MGMT promoter hypomethylation (N = 16) (p = 0.32). d The median progression-free survival was 13.1 months in patients with MGMT promoter hypermethylation (N = 11), and 7.3 months in those with MGMT promoter hypomethylation (N = 16) (p = 0.11). e The median survival times were 14.6 months in patients treated with temozolomide plus bevacizumab (N = 10), and 12.9 months in those treated with temozolomide (N = 20) (p = 0.93). f Median progression-free survival was 10.0 months in patients treated with temozolomide plus bevacizumab (N = 10), and 8.5 months in those treated with temozolomide (N = 20) (p = 0.64). Abbreviations: MGMT O-6-methylguanine DNA methyltransferase, TMZ temozolomide, Bev bevacizumab

Back to article page